Immunomedics Inc Quick Ratio (IMMU) starting from the second quarter 2020 to second quarter 2019, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Immunomedics Inc   (NASDAQ: IMMU)

Immunomedics Inc 's Quick Ratio

IMMU's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Immunomedics Inc 's Cash & cash equivalent grew by 80.44 % in the Q2 2020 sequentially, faster than Current Liabilities, this led to improvement in Immunomedics Inc 's Quick Ratio to 16.3 a new company high.

Within In Vitro & In Vivo Diagnostic Substances industry only one company has achieved higher Quick Ratio in second quarter 2020. While Quick Ratio total ranking has improved so far during the Q2 2020 to 224, from total ranking in the first quarter 2020 at 421.

Explain Quick Ratio?
How much Cash & cash equivalents IMMU´s has?
What are IMMU´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IMMU Quick Ratio (Jun 30 2020)
Q2		 (Mar 31 2020)
Q1		 (Dec 31 2019)
Q4		 (Sep 30 2019)
Q3		 (Jun 30 2019)
Q2
Y / Y Current Liabilities Change 53.62 % 9.91 % 114.26 % -77.76 % -10.91 %
Y / Y Cash & cash equivalent Change 125.48 % 22.13 % 23.18 % -36.95 % -32.27 %
Quick Ratio MRQ 16.3 9.12 9.02 6.76 11.1
IMMU's Total Ranking # 224 # 421 # 114 # 104 # 348
Seq. Current Liabilities Change 1 % -12.8 % 24.49 % 40.11 % -27.74 %
Seq. Cash & cash equivalent Change 80.44 % -11.83 % 66.08 % -14.66 % -2.26 %



Quick Ratio second quarter 2020 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 2
Healthcare Sector # 97
Overall Market # 224


Quick Ratio Statistics
High Average Low
16.3 6.06 0.54
(Jun 30 2020)   (Mar 31 2017)




Financial Statements
Immunomedics Inc 's Current Liabilities $ 60 Millions Visit IMMU's Balance sheet
Immunomedics Inc 's Cash & cash equivalent $ 976 Millions Visit IMMU's Balance sheet
Source of IMMU's Sales Visit IMMU's Sales by Geography


Cumulative Immunomedics Inc 's Quick Ratio

IMMU's Quick Ratio for the trailling 12 Months

IMMU Quick Ratio

 (Jun 30 2020)
12 Months		 (Mar 31 2020)
12 Months		 (Dec 31 2019)
12 Months		 (Sep 30 2019)
12 Months		 (Jun 30 2019)
12 Months
Y / Y Current Liabilities TTM Growth -34.69 % -41.1 % -48.03 % -64.22 % -18.63 %
Y / Y Cash & cash equivalent TTM Growth 27.56 % -9.66 % -10.73 % 1.13 % 53.38 %
Quick Ratio TTM 10.34 8.86 8.62 9.72 5.29
Total Ranking TTM # 3986 # 65 # 95 # 172 # 444
Seq. Current Liabilities TTM Growth 9.46 % 2.48 % 20.22 % -51.58 % -1.27 %
Seq. Cash & cash equivalent TTM Growth 27.76 % 5.27 % 6.62 % -11.04 % -9.52 %

Quick ratio ranking by company, industry and sector >> Back to IMMU Financial Strength Comparisons >> Go to Compare IMMU Quick Ratio to its Competitors

On the trailing twelve months basis IMMU Cash & cash equivalent more than doubled by 125.48 % in Q2 2020 year on year, faster than Current Liabilities, this led to increase in in Immunomedics Inc 's Quick Ratio to 10.34, above IMMU average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 19 other companies have achieved higher Quick Ratio than Immunomedics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2020 from 65 to 3986.

Explain Quick Ratio?
How much Cash & cash equivalents IMMU´s has?
What are IMMU´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the In Vitro & In Vivo Diagnostic Substances Industry # 20
Healthcare Sector # 851
Within the Market # 3986


trailing twelve months Quick Ratio Statistics
High Average Low
9.11 4.89 0.89
(Sep 30 2019)   (Sep 30 2017)




Companies with similar Quick Ratio in the quarter ending Jun 30 2020, within In Vitro & In Vivo Diagnostic Substances Industry Quick RatioJun 30 2020 MRQ Cash & cash equivalentJun 30 2020 MRQ Current Liabilities
Celldex Therapeutics inc   19.09 $ 206.915  Millions$ 10.841  Millions
Immunomedics Inc   16.30 $ 975.518  Millions$ 59.862  Millions
Oxford Immunotec Global Plc  15.31 $ 165.489  Millions$ 10.812  Millions
Intellia Therapeutics Inc   7.39 $ 436.804  Millions$ 59.142  Millions
Neogen Corporation  7.19 $ 343.673  Millions$ 47.795  Millions
Qc Technologies Inc   6.97 $ 18.304  Millions$ 2.626  Millions
Achieve Life Sciences Inc   6.69 $ 12.111  Millions$ 1.810  Millions
Biomerica Inc   5.85 $ 8.641  Millions$ 1.477  Millions
Volitionrx Limited  4.53 $ 21.305  Millions$ 4.708  Millions
Immucell Corporation  3.45 $ 8.195  Millions$ 2.376  Millions
Quotient Limited  3.41 $ 94.477  Millions$ 27.746  Millions

Date modified: 2026-09-08T15:10:00+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.